A recombinant prodrug type approach for triggered delivery of streptokinase.

A novel prodrug type approach for triggered delivery of thrombolytic drugs without their associated hemorrhagic effects has been proposed. Presented herein is a rapid communication of preliminary observations that suggest the feasibility of the approach. A hirulog-streptokinase fusion protein (termed "HSK") possessing active thrombolytic functions has been successfully produced using recombinant DNA technology. The prodrug and triggered release features of this approach have been demonstrated by the inhibition of the plasminogen-activating activity of HSK via binding with thrombin and reversal of this inhibition by hirudin.